Breaking News
Addicted to Fake News Over the Real Thing
Hegemon USA and Apartheid Israel: Unparalleled Rogue States
Herbs for Pain Management: A Prepper's Herbal Medicine Cabinet
Sauna Benefits Deep Dive and Optimal Use with Dr. Rhonda Patrick & MedCram
Top Tech News
How Bamboo Towers in Africa Produce Free Water
CHEAP AND EASY DIY CHICKEN COOP!
NVIDIA released a new Eye Contact feature that uses AI to make you look into the camera.
Plasma Thrusters Ran at 500% Beyond Old Power Limits
Nikola Highlights its Integrated Hydrogen Solution, Introduces New Hydrogen Energy Brand "HYLA*
Tesla Will Have Abundant 4680 Batteries in a Few Years
CIA FUNDED COMPANY TO RESURRECT EXTINCT ANIMALS UNDER THE GUISE OF CLIMATE CHANGE
MightyFly's new autonomous cargo drone carries 100 lb for 600 miles
What search engine best at "Freedom-Respecting"?
A breakthrough system can see through walls by using Wi-Fi routers
DARPA Nucleic Technology Funded to Get Virus Response to 1-60 Days
The P3 teams are developing technologies to deliver antibodies using nucleic acid technology, and achieve sufficient serum concentrations of the antibodies for protection against the pathogen within three days after administration.
DARPA has programs for Pandemic Prevention Platform, Nucleic Acids On-Demand Worldwide (NOW), and PReemptive Expression of Protective Alleles and Response Elements (PREPARE) programs.
Nucleic Acids On-Demand Worldwide (NOW)
The goal of the NOW program is to develop a mobile medical countermeasure (MCM) manufacturing platform for use in stabilization and humanitarian operations to produce, formulate, and package hundreds of doses of nucleic acid therapeutics (DNA and/or RNA) in less than 24 hours. The developed platform should be a resilient, mobile, readily accessible nucleic acid MCM manufacturing capability that enables immediate threat response anywhere the military operates with minimal user intervention.